Combining The Advisory Board Company’s research
and advisory services with Optum’s data analytics and technology
capabilities to help health care clients adapt to the changing
health care landscape.
Optum and The Advisory Board Company (NASDAQ: ABCO), announced
today that The Advisory Board Company’s health care business will
join Optum.
By bringing together distinctive information and technology
solutions with comprehensive data-driven research and advisory
capabilities, the combined organization will be better positioned
to help its members and clients respond to changing market dynamics
and improve the health system for everyone.
For more than three decades, The Advisory Board Company has
combined research, technology and consulting to improve the
performance of health care organizations. The Advisory Board
Company has achieved remarkable success serving more than 4,000
members by driving their growth, advancing care quality, reducing
care variation and optimizing their overall performance. Optum will
preserve the objectivity and enhance the range, impact and value of
The Advisory Board Company’s research for its members while
offering a broader range of advisory and technology capacities to
enhance the value it delivers to its members.
Optum helps clients deliver better experiences, quality outcomes
and reduced costs in five core areas: data analytics, pharmacy care
services, population health management, health care delivery and
health care operations. The company serves stakeholders throughout
the health care system, including more than 300 health plans and
four out of every five U.S. hospitals, as well as life sciences
companies, employers, governments and consumers.
Robert Musslewhite, CEO of The Advisory Board Company, will
continue to lead its health care advisory business.
“Joining Optum will enable us to better serve our members,
thanks to Optum’s unmatched data analytics resources, investment
capacities and operational experience in delivering large-scale
solutions and services to all health care stakeholders,” said
Musslewhite. “Our team and I look forward to working with Optum to
bring our innovative research capabilities into new, untapped
markets.”
“The Advisory Board Company is a strong fit for Optum because
they share our mission of making the health care system work better
for everyone,” said Larry Renfro, CEO, Optum. “We have great
admiration for the talent and experience of The Advisory Board’s
team and its leaders, and look forward to working alongside them to
help its members and our clients solve their biggest
challenges.”
The Board of Directors of The Advisory Board Company unanimously
approved the merger agreement and has recommended that its
stockholders adopt the merger agreement. The merger is expected to
close by the end of 2017 or in early 2018 and is contingent on the
approval of The Advisory Board Company’s stockholders and the
satisfaction or waiver of certain other closing conditions,
including U.S. antitrust clearance and the closing of the sale of
The Advisory Board Company’s education business.
The transaction is expected to be neutral to UnitedHealth
Group’s earnings per share in the first year. For transaction
details, please see The Advisory Board Company news release at
http://investors.advisoryboardcompany.com/press-releases.
About The Advisory Board Company Health Care Business
Headquartered in Washington, D.C., with offices worldwide,
Advisory Board, the health care business of The Advisory Board
Company, is a best practices firm that uses a combination of
research, technology and consulting to improve the performance of
more than 4,400 health care organizations. For more information,
visit www.advisory.com.
About Optum
Optum is a leading information and technology-enabled health
services business dedicated to helping make the health system work
better for everyone. With more than 133,000 people worldwide, Optum
delivers intelligent, integrated solutions that help to modernize
the health system and improve overall population health. Optum is
part of UnitedHealth Group (NYSE:UNH). For more information, visit
www.optum.com.
Cautionary Statement Regarding Forward-Looking
Statements
This communication includes “forward-looking statements” as
defined under U.S. federal securities laws about the proposed
transaction. Generally, the words “believe,” “expect,” “intend,”
“estimate,” “anticipate,” “plan,” “project,” “should,” “will” and
similar expressions identify forward-looking statements, which
generally are not historical in nature. These statements are based
on current plans, estimates and expectations that are subject to
risks and uncertainties. We caution that actual results could
differ materially from expected results, depending on the outcome
of certain factors, including (i) the failure to satisfy the
conditions to the completion of the transactions, including the
sale of The Advisory Board Company’s education business to Vista
Equity Partners, approval of the proposed merger by The Advisory
Board Company’s stockholders and the receipt of regulatory
approvals on the terms expected or on the anticipated schedule;
(ii) the occurrence of any event, change or other circumstance that
could give rise to the termination of the merger agreement or the
education purchase agreement; (iii) there may be a material adverse
change regarding The Advisory Board Company or its health care
business or its education business, (iv) the failure to complete or
receive the anticipated benefits from the transactions; (v)
operating costs, customer loss and business disruption (including,
without limitation, difficulties in maintaining relationships with
employees, customers, clients or suppliers) may be greater than
expected; (vi) the retention of certain key employees at The
Advisory Board Company; (vii) the parties’ ability to meet
expectations regarding the timing, completion and accounting and
tax treatments of the arrangement; (viii) risks related to
diverting management attention from ongoing business operations;
(ix) the outcome of any legal proceedings that may be instituted
against UnitedHealth Group, Optum, The Advisory Board Company or
Vista Equity Partners related to the transactions; (x) there may be
changes in economic conditions, financial markets, interest rates,
political conditions or changes in federal or state laws or
regulations; (xi) there may be changes in the market price of
Evolent Health, Inc.’s Class A common stock; and (xii) the other
factors relating to UnitedHealth Group and The Advisory Board
Company discussed in “Risk Factors” in their respective Annual
Reports on Form 10-K for the most recently ended fiscal year, and
in their other filings with the Securities and Exchange Commission
(SEC), all of which are available at http://www.sec.gov. None of
The Advisory Board Company, UnitedHealth Group or Vista Equity
Partners assume any obligation to update or revise this
communication as a result of new information, future events or
otherwise, except as otherwise required by applicable law. Readers
are cautioned not to place undue reliance on these forward-looking
statements that speak only as of the date hereof.
Additional Information and Where to Find It
The proposed merger will be submitted to the stockholders of The
Advisory Board Company for their consideration. This communication
may be deemed to be solicitation material in connection with the
proposed merger. The Advisory Board Company and UnitedHealth Group
intend to file materials relevant to the proposed merger with the
SEC, including The Advisory Board Company’s proxy statement on
Schedule 14A. This communication is not a substitute for the proxy
statement or any other document that The Advisory Board Company may
send to its stockholders in connection with the proposed merger.
BEFORE MAKING ANY VOTING DECISIONS, THE ADVISORY BOARD COMPANY’S
STOCKHOLDERS ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH
THE SEC WHEN THEY BECOME AVAILABLE, INCLUDING THE PROXY STATEMENT
FOR THE PROPOSED MERGER, BECAUSE THEY WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION. Copies of the proxy
statement and other relevant materials, when filed, will be
available free of charge on the SEC’s web site at
http://www.sec.gov or on The Advisory Board Company’s
website at
http://investors.advisoryboardcompany.com/Docs/.
Participants in Solicitation
The Advisory Board Company and its directors and executive
officers, and UnitedHealth Group and its directors and executive
officers, are deemed to be participants in the solicitation of
proxies from stockholders of The Advisory Board Company in
connection with the proposed merger.
Information about The Advisory Board Company’s directors and
executive officers and their ownership of The Advisory Board
Company’s common stock can be found in its Annual Report on Form
10-K for the year ended December 31, 2016 filed with the SEC on
March 16, 2017, in its Definitive Proxy Statement for its 2017
Annual Meeting of Stockholders filed with the SEC on April 21, 2017
and on The Advisory Board Company’s website at
https://www.advisoryboardcompany.com/.
Information about UnitedHealth Group’s directors and executive
officers can be found in its Annual Report on Form 10-K for the
year ended December 31, 2016 filed with the SEC on February 8, 2017
and on UnitedHealth Group’s website at
http://www.unitedhealthgroup.com.
Investors may obtain additional information regarding the
interest of such participants by reading the proxy statement and
other materials to be filed with the SEC in connection with
proposed merger when they become available.
Click here to subscribe to Mobile Alerts for
UnitedHealth Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170829005430/en/
OptumMatt Stearns, 202-383-6434matt.stearns@optum.comorThe
Advisory Board CompanyRobert Borchert,
202-266-6240rborchert@advisory.com
Grafico Azioni The Advisory Board Company (MM) (NASDAQ:ABCO)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni The Advisory Board Company (MM) (NASDAQ:ABCO)
Storico
Da Giu 2023 a Giu 2024